These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 19443598

  • 1. Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in HIF-1-active tumor cells.
    Kudo T, Ueda M, Kuge Y, Mukai T, Tanaka S, Masutani M, Kiyono Y, Kizaka-Kondoh S, Hiraoka M, Saji H.
    J Nucl Med; 2009 Jun; 50(6):942-9. PubMed ID: 19443598
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of [125I]IPOS as a molecular imaging probe for hypoxia-inducible factor-1-active regions in a tumor: comparison among single-photon emission computed tomography/X-ray computed tomography imaging, autoradiography, and immunohistochemistry.
    Ueda M, Kudo T, Mutou Y, Umeda IO, Miyano A, Ogawa K, Ono M, Fujii H, Kizaka-Kondoh S, Hiraoka M, Saji H.
    Cancer Sci; 2011 Nov; 102(11):2090-6. PubMed ID: 21824221
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Significance of HIF-1-active cells in angiogenesis and radioresistance.
    Harada H, Kizaka-Kondoh S, Li G, Itasaka S, Shibuya K, Inoue M, Hiraoka M.
    Oncogene; 2007 Nov 29; 26(54):7508-16. PubMed ID: 17563752
    [Abstract] [Full Text] [Related]

  • 5. Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer.
    Kizaka-Kondoh S, Itasaka S, Zeng L, Tanaka S, Zhao T, Takahashi Y, Shibuya K, Hirota K, Semenza GL, Hiraoka M.
    Clin Cancer Res; 2009 May 15; 15(10):3433-41. PubMed ID: 19417024
    [Abstract] [Full Text] [Related]

  • 6. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells.
    Harada H, Hiraoka M, Kizaka-Kondoh S.
    Cancer Res; 2002 Apr 01; 62(7):2013-8. PubMed ID: 11929818
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Construction of mutant TKGFP for real-time imaging of temporal dynamics of HIF-1 signal transduction activity mediated by hypoxia and reoxygenation in tumors in living mice.
    Hsieh CH, Kuo JW, Lee YJ, Chang CW, Gelovani JG, Liu RS.
    J Nucl Med; 2009 Dec 01; 50(12):2049-57. PubMed ID: 19910419
    [Abstract] [Full Text] [Related]

  • 9. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
    Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T.
    Cancer Res; 2007 May 01; 67(9):4157-63. PubMed ID: 17483326
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts.
    Harada H, Kizaka-Kondoh S, Itasaka S, Shibuya K, Morinibu A, Shinomiya K, Hiraoka M.
    Biochem Biophys Res Commun; 2007 Sep 07; 360(4):791-6. PubMed ID: 17624305
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers.
    Shi M, Guo XT, Shu MG, Chen FL, Li LW.
    Med Hypotheses; 2007 Sep 07; 69(1):33-5. PubMed ID: 17280792
    [Abstract] [Full Text] [Related]

  • 15. A recombinant cell-permeable p53 fusion protein is selectively stabilized under hypoxia and inhibits tumor cell growth.
    Yu Z, Wu J, Wu S, Jia P, Tong Y, Wu X, Wang Y.
    Cancer Lett; 2009 Jun 28; 279(1):101-7. PubMed ID: 19232460
    [Abstract] [Full Text] [Related]

  • 16. Dual effect of echinomycin on hypoxia-inducible factor-1 activity under normoxic and hypoxic conditions.
    Vlaminck B, Toffoli S, Ghislain B, Demazy C, Raes M, Michiels C.
    FEBS J; 2007 Nov 28; 274(21):5533-42. PubMed ID: 17916190
    [Abstract] [Full Text] [Related]

  • 17. Diameter of tumor blood vessels is a good parameter to estimate HIF-1-active regions in solid tumors.
    Harada H, Xie X, Itasaka S, Zeng L, Zhu Y, Morinibu A, Shinomiya K, Hiraoka M.
    Biochem Biophys Res Commun; 2008 Sep 05; 373(4):533-8. PubMed ID: 18586004
    [Abstract] [Full Text] [Related]

  • 18. The human HIF (hypoxia-inducible factor)-3alpha gene is a HIF-1 target gene and may modulate hypoxic gene induction.
    Tanaka T, Wiesener M, Bernhardt W, Eckardt KU, Warnecke C.
    Biochem J; 2009 Oct 23; 424(1):143-51. PubMed ID: 19694616
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and ((5-iodo-3-pyridinyl)carbonyl)norbiotinamide: two radioiodinated biotin conjugates with improved stability.
    Foulon CF, Alston KL, Zalutsky MR.
    Bioconjug Chem; 1997 Oct 23; 8(2):179-86. PubMed ID: 9095358
    [Abstract] [Full Text] [Related]

  • 20. Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.
    Balamurugan K, Luu VD, Kaufmann MR, Hofmann VS, Boysen G, Barth S, Bordoli MR, Stiehl DP, Moch H, Schraml P, Wenger RH, Camenisch G.
    Oncogene; 2009 Sep 17; 28(37):3274-85. PubMed ID: 19581925
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.